MapLight shares sink on mixed Phase 2 schizophrenia readout on July 27, 2026 Autism trial Iris (Eye) M1/M4 agonist MapLight Therapeutics Mixed readout PANSS Placebos Rating (action) readout Schizophrenia Stifel stock plunge ZEPHYR Phase 2 +